You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Read More The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
— per share
Expected Nov 5, Pre-Market